FDA Rejects Mylan’s Generic Advair

Mar 30, 2017

The U.S. FDA has rejected Mylan's generic version of GlaxoSmithKline's best-selling asthma treatment, Advair.

Advair has brought GSK more than $1 billion in annual sales every year since 2001.

According to Mylan, in conjunction with its GDUFA goal date, the company received a complete response letter from FDA regarding its ANDA for generic Advair Diskus. Mylan is in the process of reviewing this response and will provide an update on its application as soon as practicable once it has completed its review and discussed the FDA's feedback with the agency.

Read the Mylan press release

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments